

Crk-L (C-20): sc-319

BACKGROUND

SH2 and SH3 (Src homology) domains were originally identified as critical functional domains within non-receptor proteins with tyrosine kinase activity. One of the first members of the family to be identified, Crk, is a transformation-specific protein that induces elevation of cellular phosphotyrosine levels, but lacks tyrosine kinase activity itself. A second protein, Nck, consists solely of three SH3 domains and one SH2 domain, while GRB2 contains an SH2 domain flanked on both sides by SH3 domains. A member of this protein class, Crk-L, is encoded by a gene located on chromosome 22, band 11, centromeric of the chronic myelogenous leukemia breakpoint region. Crk-L encodes a 303 amino acid protein with one SH2 and 2 SH3 domains.

CHROMOSOMAL LOCATION

Genetic locus: CRKL (human) mapping to 22q11.21; Crkl (mouse) mapping to 16 A3

SOURCE

Crk-L (C-20) is an affinity purified rabbit polyclonal antibody raised against a peptide mapping at the C-terminus of Crk-L of human origin.

PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-319 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

Crk-L (C-20) is recommended for detection of Crk-L p36 of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500), immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Crk-L (C-20) is also recommended for detection of Crk-L p36 in additional species, including equine, canine, bovine, porcine and avian.

Suitable for use as control antibody for Crk-L siRNA (h): sc-35114, Crk-L siRNA (m): sc-35115, Crk-L shRNA Plasmid (h): sc-35114-SH, Crk-L shRNA Plasmid (m): sc-35115-SH, Crk-L shRNA (h) Lentiviral Particles: sc-35114-V and Crk-L shRNA (m) Lentiviral Particles: sc-35115-V.

Molecular Weight of Crk-L: 36 kDa.

Positive Controls: HeLa whole cell lysate: sc-2200, NIH/3T3 whole cell lysate: sc-2210 or A-431 whole cell lysate: sc-2201.


STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.


RESEARCH USE

For research use only, not for use in diagnostic procedures.

DATA



Crk-L (C-20): sc-319. Western blot analysis of Crk-L expression in A-431 (A) and NIH/3T3 (B) whole cell lysates.



Crk-L (C-20): sc-319. Immunofluorescence staining of methanol-fixed NIH/3T3 cells showing cytoplasmic localization (A). Immunoperoxidase staining of formalin fixed, paraffin-embedded human colon tissue showing cytoplasmic staining of glandular cells (B).

SELECT PRODUCT CITATIONS

- Ribon, V., et al. 1996. The product of the Cbl oncogene forms stable complexes *in vivo* with endogenous Crk in a tyrosine phosphorylation-dependent manner. *Mol. Cell. Biol.* 16: 45-52.
- Guerrouahen, B.S., et al. 2010. Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias. *Clin. Cancer Res.* 16: 1149-1158.
- Lucas, C.M., et al. 2010. Bcr-Abl1 tyrosine kinase activity at diagnosis, as determined via the pCrkL/CrkL ratio, is predictive of clinical outcome in chronic myeloid leukaemia. *Br. J. Haematol.* 149: 458-460.
- Wang, H., et al. 2010. The role of Crk/Dock180/Rac1 pathway in the malignant behavior of human ovarian cancer cell SKOV3. *Tumour Biol.* 31: 59-67.
- Tebbi, A., et al. 2011. TAp73 induction by nitric oxide: regulation by checkpoint kinase 1 (CHK1) and protection against apoptosis. *J. Biol. Chem.* 286: 7873-7884.
- He, Y., et al. 2011. The non-receptor tyrosine kinase Lyn controls neutrophil adhesion by recruiting the CrkL-C3G complex and activating Rap1 at the leading edge. *J. Cell Sci.* 124: 2153-2164.
- Machado-Neto, J.A., et al. 2011. Knockdown of Insulin receptor substrate 1 reduces proliferation and downregulates Akt/mTOR and MAPK pathways in K562 cells. *Biochim. Biophys. Acta* 1813: 1404-1411.
- Padmanabhan, R.A., et al. 2011. Crkl is a co-activator of estrogen receptor α that enhances tumorigenic potential in cancer. *Mol. Endocrinol.* 25: 1499-1512.

MONOS
Satisfaction
Guaranteed

Try **Crk-L (B-1): sc-365092** or **Crk-L (A-1): sc-365471**, our highly recommended monoclonal alternatives to Crk-L (C-20).